Satellite Symposia Schedule

Monday, February 07, 2022, 11:45 AM – 12:45 PM
It’s not what you think… Navigating multisystemic presentations of ASMD
Supported by Sanofi Genzyme.

Monday, February 07, 2022, 11:45 AM – 12:45 PM
Protection for Fabry patients
Supported by Takeda Pharmaceutical Company Limited.
This satellite is open only to registered attendees from outside the United States, except for the UK & Ireland. International participants only.

Monday, February 07, 2022, 5:30 PM – 7:00 PM
Late-onset Pompe disease: Bringing patient disease management into focus
Supported by Amicus Therapeutics, Inc.

Monday, February 07, 2022, 5:30 PM – 7:00 PM
Know When to Treat: Long-Term Management of Fabry Disease in Adult and Pediatric Patients
Supported by Sanofi Genzyme.

Tuesday, February 08, 2022, 11:45 AM – 12:45 PM
Changing the paradigm for the diagnosis of rare genetic diseases
Supported by BioMarin Pharmaceutical Inc.

Tuesday, February 08, 2022, 11:45 AM – 12:45 PM
Mitigating Disease Progression in Pompe Disease: Optimizing Early Diagnosis and Considering New Therapies to Improve Outcomes
CE Satellite Symposium
Accredited provider: AKH Inc., Advancing Knowledge in Healthcare
Supported by an independent educational grant from Sanofi Genzyme.

Tuesday, February 08, 2022, 5:30 PM – 7:00 PM
Precision Medicine in Lysosomal Disease: The Time Is NOW!
CE Satellite Symposium
Accredited provider: Postgraduate Institute for Medicine (PIM)
Jointly provided by PIM and Saterdalen & Associates, LLC
Supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Tuesday, February 08, 2022, 5:30 PM – 7:00 PM
Fabry Disease: The Impact on Women and Girls
Supported by Sanofi Genzyme.

Wednesday, February 09, 2022, 11:45 AM – 12:45 PM
Shifting the Treatment Paradigm: Choices in Late-onset Pompe Disease
Supported by Sanofi Genzyme.

Wednesday, February 09, 2022, 11:45 AM – 12:45 PM
My Fabry Frame of Mind
Supported by Amicus Therapeutics, Inc.
This satellite is open only to registered attendees from outside the United States. International participants only.

Wednesday, February 09, 2022, 5:30 PM – 7:00 PM
Evaluating Fabry Disease in the Real World
Supported by Chiesi Global Rare Diseases.

Wednesday, February 09, 2022, 5:30 PM – 7:00 PM
Understanding the Fundamentals of Investigational Gene Therapy for Lysosomal Disorders: A Focus on Pompe Disease
Supported by Spark Therapeutics.

Thursday, February 10, 2022, 11:45 AM – 12:45 PM
Individualising Enzyme Replacement Therapy in Patients Living with Late-onset Pompe Disease
CE Satellite Symposium
Accredited provider: PeerVoice
Supported by an independent educational grant from Amicus Therapeutics, Inc.

Thursday, February 10, 2022, 11:45 AM – 12:45 PM
Real world evidence in Fabry disease: Bridging the gap between clinical studies and clinical practice
Supported by Sanofi Genzyme.
This satellite is open only to registered attendees from outside the United States. International participants only.

Thursday, February 10, 2022, 5:30 PM – 7:00 PM
Critical role of GCS inhibition in the GSL hub of Lysosomal Diseases
Supported by Sanofi Genzyme.
This satellite is open only to registered attendees from outside the United States. International participants only.

Thursday, February 10, 2022, 5:30 PM – 7:00 PM
Fabry in Females: More Than Meets the Eye
Supported by Amicus Therapeutics, Inc.

Friday, February 11, 2022, 6:30 AM – 7:45 AM
Importance of M6P: Scientific Breakthrough Enables Development of More Potent Treatments for Lysosomal Diseases
Supported by M6P Therapeutics.

Friday, February 11, 2022, 6:30 AM – 7:45 AM
Shortening the journey to diagnosis in MLD: What can we do now and what do we need to learn?
Supported by Takeda Pharmaceutical Company Limited.